Hsp90 inhibitors as novel cancer chemotherapeutic agents.

By L. Neckers. Trends in Molecular Medicine, 2002

663 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/20a84dcaf71b52ff751908d62db1ea9ce603be80

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Stephen L. Abrams
2. W. Chappell
3. E. T. Wong
4. A. Martelli
5. Mohamed Hassan
6. Ali AbuAlmaaty
7. M. Milella
8. C. Evangelisti

Citations in the corpus

• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. (2007, background): “However ERK2 has been postulated to have pro-proliferative effects while ERK1 has anti-proliferative effects [171].”
• Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “Several key Hsp90 proteins are involved in the processes characteristic to the malignant phenotype, such as invasion, angiogenesis metastasis, and treatment resistance [268–270].”